Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 28 04:00PM ET
72.70
Dollar change
-0.32
Percentage change
-0.44
%
IndexNDX, S&P 500 P/E16.14 EPS (ttm)4.50 Insider Own0.10% Shs Outstand1.25B Perf Week-0.68%
Market Cap90.57B Forward P/E9.74 EPS next Y7.46 Insider Trans-1.56% Shs Float1.24B Perf Month-8.06%
Income5.66B PEG3.15 EPS next Q1.58 Inst Own87.12% Short Float1.60% Perf Quarter-2.96%
Sales27.06B P/S3.35 EPS this Y5.82% Inst Trans0.85% Short Ratio2.69 Perf Half Y-5.63%
Book/sh18.33 P/B3.97 EPS next Y4.97% ROA9.04% Short Interest19.88M Perf Year-10.12%
Cash/sh6.70 P/C10.85 EPS next 5Y5.12% ROE25.71% 52W Range71.37 - 87.86 Perf YTD-10.26%
Dividend Est.3.14 (4.32%) P/FCF12.20 EPS past 5Y1.55% ROI12.16% 52W High-17.26% Beta0.20
Dividend TTM3.00 (4.13%) Quick Ratio1.27 Sales past 5Y4.16% Gross Margin77.94% 52W Low1.86% ATR (14)1.40
Dividend Ex-DateMar 14, 2024 Current Ratio1.43 EPS Y/Y TTM23.94% Oper. Margin33.96% RSI (14)36.56 Volatility1.24% 1.66%
Employees18000 Debt/Eq1.12 Sales Y/Y TTM-0.10% Profit Margin20.93% Recom2.23 Target Price86.49
Option/ShortYes / Yes LT Debt/Eq1.04 EPS Q/Q-12.32% Payout66.62% Rel Volume0.57 Prev Close73.02
Sales Surprise0.20% EPS Surprise-2.18% Sales Q/Q-2.75% EarningsFeb 06 AMC Avg Volume7.39M Price72.70
SMA20-2.54% SMA50-8.11% SMA200-6.45% Trades Volume4,183,187 Change-0.44%
Date Action Analyst Rating Change Price Target Change
Feb-22-24Downgrade Truist Buy → Hold $91 → $82
Nov-09-23Initiated Deutsche Bank Hold $75
Sep-08-23Upgrade BofA Securities Neutral → Buy $88 → $95
Sep-06-23Initiated HSBC Securities Reduce $71
Jul-24-23Reiterated Barclays Equal Weight $81 → $80
May-16-23Upgrade BMO Capital Markets Market Perform → Outperform $90 → $100
Apr-28-23Resumed Piper Sandler Overweight $105
Jan-03-23Downgrade RBC Capital Mkts Outperform → Sector Perform $87
Dec-13-22Resumed BofA Securities Neutral $85
Dec-09-22Downgrade DZ Bank Buy → Hold $90
Feb-28-24 05:15PM
Feb-27-24 10:00AM
Feb-26-24 04:05PM
08:30AM
08:15AM
07:04AM Loading…
Feb-24-24 07:04AM
05:52AM
Feb-22-24 09:00AM
Feb-21-24 04:37PM
Feb-20-24 04:05PM
09:25AM
07:00AM
Feb-19-24 01:46PM
Feb-16-24 05:43AM
Feb-15-24 06:37PM
04:13PM Loading…
04:13PM
Feb-13-24 09:24AM
08:30AM
Feb-12-24 04:44PM
04:15PM
01:27PM
12:27PM
12:03PM
11:09AM
09:57AM
09:45AM
09:18AM
08:44AM
08:42AM
08:38AM
08:33AM Loading…
08:33AM
08:30AM
06:08AM
Feb-10-24 08:30AM
Feb-09-24 11:00AM
Feb-08-24 01:46PM
01:41PM
04:33AM
Feb-07-24 11:03PM
04:12PM
03:56PM
03:48PM
01:56PM
01:17PM
10:40AM
10:19AM
10:18AM
09:45AM
09:26AM
08:52AM
07:33AM
Feb-06-24 11:00PM
06:30PM
04:47PM
04:19PM
04:17PM
04:17PM
04:06PM
04:05PM
04:02PM
08:15AM
06:43AM
Feb-02-24 08:28AM
Feb-01-24 04:31PM
09:15AM
Jan-30-24 10:00AM
08:30AM
08:10AM
Jan-29-24 05:50PM
05:00PM
06:27AM
Jan-26-24 08:00AM
Jan-23-24 06:00PM
04:05PM
11:37AM
09:45AM
07:35AM
Jan-22-24 08:34PM
08:11PM
06:08PM
04:08PM
03:45PM
03:40PM
03:39PM
02:19PM
01:19PM
01:09PM
11:28AM
11:23AM
10:17AM
09:02AM
08:55AM
08:30AM
08:30AM
07:46AM
07:20AM
Jan-18-24 02:41PM
01:03AM
Jan-17-24 06:00PM
02:18PM
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILEAD SCIENCES, INC.10% OwnerFeb 12Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
GILEAD SCIENCES, INC.10% OwnerJan 29Buy21.0015,238,095319,999,99530,061,124Jan 31 05:00 PM
Dickinson Andrew DChief Financial OfficerJan 16Sale85.785,000428,900101,534Jan 17 06:01 PM
Mercier JohannaChief Commercial OfficerJan 09Sale85.238,242702,46682,729Jan 10 03:58 PM
Dickinson Andrew DChief Financial OfficerOct 17Sale80.005,000400,017104,003Oct 18 04:31 PM
Parsey MerdadChief Medical OfficerSep 12Sale76.991,501115,56270,130Sep 13 06:50 PM
Dickinson Andrew DChief Financial OfficerJul 20Sale80.005,000400,000107,587Jul 21 05:30 PM
GILEAD SCIENCES, INC.10% OwnerJun 28Buy19.261,010,00019,452,60014,823,029Jun 30 03:12 PM
GILEAD SCIENCES, INC.10% OwnerJun 27Buy3.752,930,87010,990,76216,635,286Jun 28 05:17 PM
Parsey MerdadChief Medical OfficerJun 13Sale76.901,485114,19729,402Jun 14 05:48 PM
Parsey MerdadChief Medical OfficerMar 13Sale78.996,126483,89370,130Mar 14 06:20 PM
Lofton Kevin EDirectorMar 09Option Exercise52.388,442442,1928,442Mar 10 05:23 PM
Parsey MerdadChief Medical OfficerMar 01Sale79.9612,9841,038,22570,130Mar 02 07:01 PM